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Introduction
Osteoclasts, the exclusive bone resorptive cells, play an 
important role not only in physiological bone develop-
ment and remodeling, but also function actively as a 
central pathogenic factor (‘culprit’) leading to musculo-
skeletal tissue damage and accelerating pathogenesis of 
diseases characterized by inﬂ   ammatory osteolysis, in-
clud  ing rheumatoid arthritis, psoriatic arthritis, perio-
dontitis and peri-prosthetic loosening. In these diseases, 
abnormally enhanced osteoclast formation and activity 
cause bone loss that can result in pain, deformity, 
osteopenia, osteoporosis and even fracture.
It has been extensively documented that a variety of 
inﬂ  ammatory molecules, such as TNF-α, IL-1β, IL-17, 
and Toll-like receptor (TLR) ligands, promote osteo-
clasto  genesis synergistically with RANKL (Receptor 
activator of NF-κB ligand) to induce pathological bone 
resorption in inﬂ  ammatory settings. In addition, there is 
a great deal of recent evidence that various inﬂ  ammatory 
factors produced by activated immune cells act as anti-
osteoclastogenic factors by diﬀ  erent  mechanisms 
(Figure 1). Suppression of osteoclastogenesis by inﬂ  am-
matory factors and cytokines functions as a feedback 
inhibition system that limits bone resorption and tissue 
damage associated with infection or inﬂ  ammation. Th  ese 
inﬂ   ammatory factors can suppress osteoclastogenesis 
directly by inhibiting diﬀ   erentiation of osteoclast pre-
cursors or indirectly by regulating diﬀ  erentiation  and 
expression of RANKL and osteoprotegerin (OPG) by 
mesenchymal cells, such as osteoblastic/stromal cells and 
synovial ﬁ  broblasts, or by T cells.
Osteoclast diﬀ   erentiation is physiologically triggered 
by RANKL in the presence of macrophage colony-
stimulating factor (M-CSF) and unknown co-stimulatory 
factors. Upon RANK stimulation, a broad range of signal-
ing cascades are activated, such as canonical and non-
canonical NF-κB pathways, protein tyrosine kinases, such 
as BtK/Tec, calcium signaling, and mitogen-activated 
protein kinase (MAPK) pathways, including p38 and Erk. 
Th   ese signaling cascades, which are reviewed in depth in 
the accompanying review by Zwerina and colleagues [1], 
lead to induction of the transcription factor NFATc1 
(Nuclear factor of activated T cells, cytoplasmic 1), which 
serves as a ‘master regulator’ of osteoclastogenesis, 
together with other transcription factors, such as NF-κB 
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© 2011 BioMed Central Ltdand c-fos, to drive osteoclastogenesis [2] (Figure 2). More 
recently, transcriptional repressors that suppress RANKL-
induced gene expression and diﬀ  erentiation have been 
described (Figure 2). Th  ese repressors can work as 
homeostatic factors in regulating osteoclasto  genesis in 
physiological bone development and re  modeling, and 
also as feedback inhibitors that limit bone resorption 
asso  ciated with inﬂ  ammation.  Th   e extent of bone 
destruc  tion in inﬂ  ammatory diseases is determined by 
the balance between osteoclastogenic and anti-osteo-
clastogenic factors.
Cytokines
IL-4/IL-13 and granulocyte-macrophage colony-
stimulating factor
IL-4 and IL-13 have pleiotropic immune functions and 
are produced by Th  2 lymphocytes, although IL-13 can 
also be produced by stromal cells. Since IL-4 and IL-13 
utilize closely related receptor complexes, they have 
many overlapping features, including downstream signal-
ing and some biological functions. IL-4, more eﬀ  ectively 
than IL-13, directly prevents osteoclast precursors from 
diﬀ  erentiating into osteoclasts in a signal transducer and 
activator of transcription (STAT)6-dependent manner 
[3,4]. IL-4 suppresses RANK expression, NF-κB, MAPK 
and calcium signaling, and expression of NFATc1 and c-
Fos during osteoclasto  genesis [3-5]. In addition, IL-4 
inhibits bone resorption and actin ring formation in 
human mature osteoclasts by suppressing NF-κB and 
calcium signaling. On the other hand, IL-4 and IL-13 
indirectly suppress osteoclasto  genesis by inhibiting 
RANKL but enhancing OPG expres  sion in osteoblastic 
cells [3,4]. Although IL-4 suppresses spontaneous or 
para  thyroid hormone-related protein (1-34)-stimulated 
osteo  clast formation in mice, IL-4 transgenic mice exhibit 
an osteoporotic phenotype that is attributed to a more 
dominant suppressive eﬀ  ect of IL-4 on osteoblast forma-
tion in vivo relative to its role in suppressing osteo  clasto-
genesis. Th   us, it is important to note that the net eﬀ  ect of 
IL-4 on bone turnover in vivo represents an integrated 
outcome of its inﬂ  uence on various cell populations.
Granulocyte-macrophage colony-stimulating factor 
(GM-CSF) inhibits osteoclastogenesis by diverting osteo-
clast precursors to a macrophage lineage [6]. Th  e  osteo-
clast suppressive mechanism was recently suggested to 
involve proteolytic cleavage of cell surface M-CSF 
receptor after treatment with GM-CSF and IL-4 [7]. Th  e 
combination of GM-CSF and IL-4 enhances expression 
and activity of TACE (TNF-α converting enzyme)/
ADAM17 (a disintegrin and metalloproteinase 17) in 
human monocytes. Th   is results in cleavage of cell surface 
M-CSF receptor, leading to disruption of M-CSF signal-
ing and thereby suppressing osteoclastogenesis and 
divert  ing the cells toward the dendritic cell lineage [7].
Figure 1. Regulation of osteoclast diff  erentiation. Osteoclasts are derived from myeloid precursors. Macrophage colony-stimulating factor 
(M-CSF) induces myeloid precursors to diff  erentiate to osteoclast precursors that express RANK (Receptor activator of NF-κB) and TREM2 (Triggering 
receptor expressed by myeloid cells-2) receptors. Upon RANK ligand (RANKL) stimulation and ITAM (Immunoreceptor tyrosine-based activation 
motif) activation, osteoclast precursors undergo further diff  erentiation to mononuclear osteoclasts with NFATc1 (Nuclear factor of activated 
T cells, cytoplasmic 1) induction and express osteoclast-related genes such as those encoding TNF-receptor associated protein (TRAP), cathepsin K 
(CtsK) and αvβ3. Mononuclear osteoclasts then fuse to multinuclear osteoclasts and function as polarized bone resorbing cells. This process of 
osteoclast diff  erentiation is regulated by various transcription factors and exogenous factors at diff  erent stages. Infl  ammatory factors that promote 
osteoclastogenesis are shown in red. Inhibitors of osteoclastogenesis are shown in blue. Calc, calcitonin; Calc R, calcitonin receptor; CSF-1R, 
colony stimulating factor 1 receptor; DC-STAMP, dendritic cell-specifi  c transmembrane protein; ECM, extracellular matrix; GM-CSF, granulocyte-
macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; MITF, microphthalmia-associated transcription factor; OPG, 
osteoprotegerin; TLR, Toll-like receptor.
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IL-10, produced by T and B lymphocytes and myeloid 
lineage cells, is predominantly an immunosuppressive 
and anti-inﬂ  ammatory cytokine that is best known as a 
potent deactivator of dendritic cells and macrophages. It 
plays a critical role in limiting tissue injury during 
infections and in preventing autoimmunity by limiting 
the duration and intensity of immune and inﬂ  ammatory 
reactions. A large body of work has established an impor-
tant role for IL-10 in suppressing osteoclastogenesis in 
vitro and in vivo [8-12]. For example, IL-10 is expressed 
in periodontitis, and IL-10 polymorphisms have been 
linked to periodontitis in multiple studies. In 
periodontitis, IL-10 is a key negative regulator of bone 
resorption [8,9]. IL-10 directly inhibits osteoclast 
precursors by suppres  sing RANKL-induced NFATc1, 
c-Fos and c-Jun expression [10,11]. Inhibition of RANKL 
expression and an increase in OPG expression due to 
IL-10 were found in dental follicle cells that support 
osteoclastogenesis, suggesting that IL-10 can also in-
directly inhibit osteoclastogenesis via modulation of 
RANKL and OPG expression. A key biological activity of 
IL-10 is to attenuate inﬂ  ammation by suppressing TNF-α 
and IL-1 production and by antagonizing TNF-α and 
IL-1 function; thereby, IL-10 may suppress TNF-α- and 
IL-1-stimulated bone resorp  tion. Recently, our lab, using 
human osteoclast pre  cursors, showed that IL-10 inhibits 
calcium signaling by suppressing transcription of 
TREM-2, an important co-stimulatory receptor for 
osteo  clastogenesis. Downregu  lation of TREM-2 (Trigger-
ing receptor expressed by myeloid cells-2) expression 
leads to diminished calcium/calmodulin-dependent 
protein kinase (CaMK)-MEK-ERK activation induced by 
RANKL [12].
IL-27
IL-27 is produced by antigen-presenting cells and belongs 
to the IL-12 family of cytokines. IL-27 has pleiotropic 
immune functions with either activating or suppressive 
roles in various infectious and inﬂ  ammatory models. Th  e 
IL-27 receptor is an IL-27Ra (WSX-1)/gp130 hetero-
dimer. IL-27 mildly suppresses osteoclast diﬀ  erentiation 
in murine systems, potentially due to the low levels of 
WSX-1 expression on murine osteoclast precursors, 
limit  ing the response of these cells to IL-27 [13-15]. 
Aggravated arthritic bone erosions and enhanced osteo-
clastogenesis were observed in Escherichia coli cell wall 
lysate-induced arthritis models in WSX-1 knockout mice 
compared to wild-type mice [14]. It should, however, be 
noted that the enhanced inﬂ   ammation and excessive 
Th  17 cells in WSX-1 knockout arthritis models could 
also explain the increase in osteoclastogenesis [14]. On 
the other hand, our lab and other groups [13,14] reported 
that IL-27 potently inhibits RANKL-induced human 
osteoclastogenesis and osteoclastic resorptive activity in 
vitro by downregulation of RANK and TREM-2 expres-
sion, inhibition of RANKL-activated ERK, p38 and 
NF-κB signaling, and by suppression of AP-1 (c-Fos and 
c-Jun) and NFATc1 expression in human osteoclast pre-
cursors. IL-27-induced STAT1 activation also partially 
contributes to its inhibitory function [14]. While expres-
sion of IL-27 is observed in human rheumatoid arthritis, 
synovial ﬂ  uid macrophages harvested from active rheu-
matoid arthritis patients are refractory to IL-27 [13]. Th  is 
suggests that IL-27 has the capacity to protect bone tissue 
from resorption, but this homeostatic role of IL-27 might 
be compromised in an active inﬂ  ammatory  micro-
environment, such as occurs in RA.
Interferons
IFN-γ, the sole type II IFN, is a product of innate immune 
cells and Th   1 cells. In bone marrow-derived macrophage 
culture systems, IFN-γ strongly inhibits osteoclasto-
genesis [16] by sup  pres  sing RANK signaling via rapid 
TNF receptor-asso  ciated factor (TRAF)6 degradation in 
murine osteoclast precursors [16]. IFN-γ also inhibits 
human osteoclasto  genesis, but TRAF6 expression is not 
Figure 2. Transcriptional regulatory network for 
osteoclastogenesis. RANK (Receptor activator of NF-κB) signaling 
together with calcium signaling drives expression of NFATc1 (Nuclear 
factor of activated T cells, cytoplasmic 1) and its targets, resulting in 
osteoclastogenesis. This process also requires releasing the ‘brakes’ 
on NFATc1 expression and osteoclastogenesis that are imposed by 
transcriptional repressors, including inhibitors of diff  erentiation/
DNA binding (Ids), MafB (v-maf musculoaponeurotic fi  brosarcoma 
oncogene family protein B), interferon regulatory factor (IRF)-8 and B 
cell lymphoma 6 (Bcl6). There is crosstalk between the activating and 
suppressive pathways, as Blimp1 (B lymphocyte-induced maturation 
protein-1) that is induced by NFATc1 suppresses expression of MafB, 
IRF-8 and Bcl6. ITAM, immunoreceptor tyrosine-based activation 
motif; MAPK, mitogen-activated protein kinase.
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through distinct mecha  nisms in humans versus mice. 
Our lab recently found that IFN-γ, alone or in synergy 
with TLR stimulation, suppresses expression of the M-
CSF receptor c-Fms, c-Fms’s target RANK, and co-
stimulatory receptor TREM2 in human osteoclast 
precursors [17]. In both collagen-induced arthritis and 
lipopolysaccharide-induced inﬂ   am ma tory  bone 
resorption mouse models, loss of IFN-γ receptor leads to 
enhanced osteoclast formation and bone destruction 
[16,18]. IFN-γ also inhibits osteoclast formation to 
prevent tumor-associated bone loss [19]. Th  ese data 
support an inhibitory role of IFN-γ in osteo  clastogenesis 
in vivo. However, administration of re  combi  nant IFN-γ 
to rodents or osteopetrotic patients stimulates osteoclast 
formation and bone erosion [20,21]. Th  ese  contradictory 
observations of the in vivo role of IFN-γ may result from 
diﬀ  erences in the disease models and, more importantly, 
the impact of IFN-γ on various cell types. For example, 
recent data suggest that IFN-γ can not only directly 
inhibit diﬀ  erentiation of osteoclast precursors, but can 
also indirectly promote osteo  clasto  genesis by stimulating 
T-cell activation and secretion of the osteoclastogenic 
factors RANKL and TNF-α [22].
Type I IFNs, IFN-α and IFN-β, have also been impli-
cated in suppression of bone resorption. During osteo-
clastogenesis, RANKL induces IFN-β expression in 
osteo  clast precursors, and IFN-β, in turn, functions as a 
negative-feedback regulator to suppress osteoclast 
diﬀ  erentiation by decreasing c-Fos expression [23]. Mice 
deﬁ  cient in the type I IFN receptor component IFNAR1 
spontaneously develop severe osteopenia with enhanced 
osteoclastogenesis due to interference of this feedback 
loop [23]. STAT3 and SOCS (Suppressor of cytokine 
signal  ing) proteins downstream of Jak1 are also likely 
involved in the IFN-β-induced inhibition of osteoclasto-
genesis, and the ubiquitin-mediated degradation of Jak1 
after RANKL stimulation may limit the suppressive eﬀ  ect 
of IFN-β on osteoclastogenesis [24-26]. IFN-α also blunts 
in vitro osteoclastogenesis, but exogenous IFN-α has no 
obvious eﬀ  ect on bone turnover in vivo. Interestingly, 
type I IFNs appear to protect from erosive arthritic 
lesions in the setting of an IFN-driven mouse model of 
systemic lupus erythematosus, potentially explaining the 
lack of erosive arthritis in human systemic lupus erythe-
matosus [27].
Additional inhibitory cytokines: TRAIL, IL-12, IL-18, IL-6
TRAIL (TNF-related apoptosis inducing ligand), a TNF 
family member, impedes osteoclast diﬀ  erentiation [28] 
and induces apoptosis of osteoclasts [29]. IL-12 plays an 
inhibitory role in osteoclastogenesis, but it is still contro-
versial whether IL-12 directly inhibits osteoclast pre-
cursors or targets other cell types such as stromal/
osteoblastic cells or T cells to indirectly suppress osteo-
clasto  genesis [30]. Apoptosis induced by interactions 
between IL-12-induced FasL and TNF-α-induced Fas 
contributes to the inhibitory mechanisms of IL-12 in 
TNF-α-induced osteoclastogenesis  [31]. IL-18 inhibits 
osteo  clastogenesis by a variety of mechanisms, including 
stimulation of GM-CSF [32] and induction of IFN-γ and 
OPG. IL-18 alone or synergistically with IL-12 inhibits 
TNF-α-induced osteoclastogenesis through Fas-FasL-
induced apoptosis. IL-18 is induced in rheumatoid 
arthritis, but contrarily it indirectly stimulates osteo-
clasto  genesis via its induction of RANKL on synovial 
T cells. IL-6 has been regarded as a stimulator of osteo-
clastogenesis and bone resorption by stimulating 
osteoblastic/stromal cell-mediated osteoclast diﬀ  erentia-
tion, but recent studies described an opposite eﬀ  ect of 
IL-6 that directly targets osteoclast precursors to 
suppress their diﬀ  erentiation [33,34].
Toll-like receptors and interplay with interferons
TLRs are the best characterized ‘pattern recognition 
receptors’ that recognize conserved microbial molecules 
and mediate immune and inﬂ   ammatory cellular res-
ponses to infection and microbial products and in some 
cases responses to endogenous factors generated during 
cell death, inﬂ  ammation, and tissue damage. Activation 
of various TLRs directly inhibits the early stages of 
RANKL-induced osteoclastogenesis [35,36]. Th  e under-
lying molecular mechanisms include TLR-induced 
production of IFN-β that suppresses RANKL-induced c-
Fos, and inhibition of NFATc1 by decreased JNK activa-
tion in response to TLR ligands [37]. However, in a 
human osteoclast culture system, TLRs can inhibit human 
osteoclastogenesis independently of type I IFNs [17]. 
TLR ligands can suppress human osteoclastogenesis by 
inhibiting expression of c-Fms, RANK and TREM2, 
thereby rendering osteoclast precursors refractory to M-
CSF and RANKL stimulation [17]. Inhibition of RANK 
expression by TLRs was also observed in murine osteo-
clast precursors but to a lesser extent [17], suggesting 
that TLR-induced inhibition of osteoclastogenesis can be 
mediated by distinct IFN-dependent and IFN-indepen-
dent mechanisms that can act in parallel. Moreover, 
TLRs cooperate with IFN-γ to inhibit osteoclastogenesis 
by synergistically suppressing expression of RANK and c-
Fms [17]. Th   ese data revealed a complex interplay between 
TLRs and IFN-γ in the inhibition of osteoclastogenesis, 
and new mechanisms by which TLRs and IFN-γ prevent 
osteoclast precursors from diﬀ  erentiating to osteoclasts, 
while directing them toward becoming inﬂ  ammatory 
macrophages. Interferon regulatory factor (IRF)-8, 
induced by IFN-γ, is a critical negative regulator for 
osteo  clastogenesis in humans and mice, and its down-
regulation by RANKL is essential for osteoclastogenesis 
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IRF-8 is abrogated by TLR activation (Zhao B et al., 
unpublished data). Th  e inhibitory eﬀ   ect of TLRs on 
osteo  clastogenesis is compromised by IRF-8 deﬁ  ciency 
[38], suggesting that regulation of IRF-8 is involved in the 
mechanisms by which TLRs and IFN-γ inhibit 
osteoclastogenesis.
TLRs are activated during acute infection, during 
chronic microbial colonization and invasion as occur in 
periodontitis, and during chronic sterile inﬂ  ammation as 
occurs in rheumatoid arthritis, most likely by tissue 
degradation products. TLRs are highly expressed on 
hematopoietic cells and are also expressed on various 
other cell types, including epithelial cells, ﬁ  broblasts, and 
osteoblasts. Th  erefore, it is not surprising that, in con-
trast to their direct inhibitory eﬀ  ect on osteoclast pre-
cursors, TLRs can stimulate inﬂ  ammatory osteolysis in 
vivo by aﬀ  ecting various cell populations and by distinct 
mechanisms. TLRs have been implicated in the induction 
of RANKL and TNF-α expression on osteoblastic/
stromal cells and thus are involved in stimulating 
osteoblast/stromal cell-mediated osteoclastogenesis and 
bone resorption [39]. In addition, TLRs are among the 
most potent inducers of inﬂ  ammatory cytokines such as 
TNF-α and IL-1, which then act to increase RANKL 
expression on stromal cells and also synergize with 
RANK signals to drive osteoclastogenesis. Furthermore, 
TLR activation accelerates diﬀ  erentiation of committed 
osteoclasts, and promotes mature osteoclast survival 
[39-41]. Th   us, the net eﬀ  ect of TLRs on osteoclastogenesis 
in vivo is mediated by various cell types and is determined 
by the potency of pro-osteoclastogenic versus anti-
osteoclastogenic mechanisms.
Cytotoxic T-lymphocyte antigen 4 and regulatory 
T cells
Recent exciting work has identiﬁ  ed a role for regulatory 
T cells (Tregs) in restraining osteoclastogenesis and 
limit  ing bone resorption [42,43]. Tregs suppress osteo-
clast precursors directly by a mechanism predominantly 
dependent on cytotoxic T-lymphocyte antigen 4 (CTLA-4). 
CTLA-4 is expressed on the surface of activated T cells 
and Tregs and transmits an inhibitory signal to T cells 
after binding to its cognate ligands, CD80 and CD86 (also 
known as B7.1 and B7.2), on antigen-presenting cells. 
Recent work showed that CTLA-4, which is constitutively 
expressed by Tregs, directly inhibits osteoclast formation 
by binding to CD80 and CD86 expressed by osteoclast 
precursors. Th   is suggests that CTLA-4-mediated ligation 
of its counter-receptors CD80 and CD86 delivers a 
negative signal to osteoclast precursors, and provides a 
potential new explanation for the anti-erosive eﬀ  ect of 
abatacept, a CTLA-4 immunoglobulin fusion protein 
used for the treatment of rheumatoid arthritis [42,43].
Inhibitory signaling molecules
NF-κB p100
Th   e NF-κB family comprises RelA (p65), RelB, c-Rel, NF-
κB1 (p50 and its precursor p105), and NF-κB2 (p52 and 
its precursor p100). NF-κB activation is elicited by two 
major signaling pathways; the classical pathway mainly 
involves IκB kinase-β-induced IκBα degradation and 
subsequent RelA/p50 activation, and the alternative 
pathway involves NF-kappa-B-inducing kinase-induced 
p100 processing to p52 and RelB/p52 activation. Th  ere  is 
crosstalk between these two pathways, and NF-κB 
activation from these two pathways plays important 
positive roles in inducing osteoclastogenesis [2]. On the 
other hand, recent emerging evidence shows that NF-κB 
p100 functions as a negative regulator of osteo  clasto-
genesis by binding to NF-κB complexes and preventing 
their nuclear translocation. Cytosolic accumulation of 
p100 impairs osteoclastogenesis, whereas p100 deﬁ  ciency 
leads to enhanced osteoclastogenesis that contributes to 
an osteopenic phenotype in vivo [44,45]. TNF-α, unlike 
RANKL, does not seem to activate the alternative NF-κB 
pathway eﬃ   ciently, as it induces an accumulation of p100 
in osteoclast precursors via induction of TRAF3, thus 
limiting TNF-α-induced osteoclastogenesis [44]. TNF-Tg 
mice lacking NF-κB p100 exhibit more severe joint 
erosion than that of TNF-Tg littermates [44]. Although 
there is some controversy whether TNF-α positively 
regu  lates osteoclastogenesis [44,46], these data suggest 
that blockade of NF-κB p100 processing might represent 
a novel therapeutic strategy for inﬂ  ammatory bone loss 
as occurs in RA.
Cytosolic phosphatase: SHIP1
SHIP1 (Src homology 2-containing inositol-5-phos  pha-
tase 1) is preferentially expressed in hematopoietic cells, 
including T and B lymphocytes, mast cells and macro-
phages. M-CSF induces tyrosine phosphorylation of 
SHIP1 and the association of SHIP1 with c-fms via the 
adaptor protein Shc, whereby SHIP1 speciﬁ  cally  de-
phosphorylates phosphatidylinositol 3,4,5-triphosphate 
and thus inactivates phosphatidylinositide-3-kinase/Akt-
mediated signaling. Genetic evidence from SHIP1-
deﬁ  cient mice showed that SHIP1 negatively regulates 
osteoclast formation and function. Compared to wild-
type mice, SHIP1-deﬁ  cient mice exhibit increased pro-
lifera  tion of osteoclast precursors with hypersensitivity 
to M-CSF and RANKL, and increased osteoclasts with 
prolonged survival and enhanced bone resorptive 
activity, thus leading to an osteoporotic phenotype [47]. 
SHIP1 suppresses osteoclastogenesis and bone erosions 
in K/BxN mouse serum-induced inﬂ  ammatory arthritis 
models [48]. Th   e underlying mechanisms of the 
suppressive eﬀ  ect of SHIP1 on osteoclastogenesis involve 
negative regulation of M-CSF-dependent Akt activity and 
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regulation of cyclin-dependent kinase inhibitor p27, and 
negative regulation of retinoblastoma and cell prolifera-
tion [48]. A recent study revealed a novel mechanism in 
which SHIP1 interacts with DAP12 (DNAX-activating 
protein of 12 kDa) via its SH2 domain, thereby directly 
blocking the binding and activation of phosphatidyl-
inositide-3-kinase, and thus limiting TREM2- and 
DAP12-mediated co-stimulatory signaling for osteo  clasto-
genesis [49]. It is also interesting to note the morpho-
logical and functional similarities between SHIP1 
knockout osteoclasts and osteoclasts in patients with 
Paget’s disease, and similar high IL-6 expression [47]. 
However, the possibility of SHIP1 involvement in Paget’s 
disease requires genetic analysis and additional support-
ing evidence.
Notch signaling pathway
Th   e Notch signaling pathway regulates cell proliferation, 
diﬀ  erentiation and survival. In mammalian cells, there 
are four Notch receptors (Notch 1 to 4) and ﬁ  ve notch 
ligands (Jagged1, Jagged2, Delta-like (DLL)1, DLL3, and 
DLL4). Ligation of Notch receptors by their ligands leads 
to proteolytic cleavage of Notch by ADAM family 
proteases that releases the extracellular domain followed 
by intramembranous cleavage by γ-secretase that releases 
the Notch intracellular domain. Th  e Notch intracellular 
domain translocates to the nucleus, binds to the DNA-
binding protein RBP-J (recombinant recognition 
sequence binding protein at the Jκ site; also named CSL 
or CBF1), and activates Notch target genes such as Hes 
and Hey. Induction of Notch ligand Jagged1 and expres-
sion of Notch receptors 1, 2, and 3 were observed during 
RANKL-induced osteoclastogenesis [50-52]. Some 
investi  gators found that activation of the Notch signaling 
pathway inhibits RANKL-induced osteoclast diﬀ  eren-
tiation [50,51], whereas others described the opposite 
[52]. Th  e genetic evidence obtained by using bone 
marrow-derived macrophages from Notch 1/2/3 knock-
out mice or Notch 1 or Notch 3 knockout mice, however, 
solidify the ﬁ  nding that Notch negatively regulates osteo-
clastogenesis [51]. Th   e osteoclast inhibi  tory mechanisms 
include the suppression of osteoclast precursor 
proliferation by Notch, likely through inhibi  tion of the 
expression of the M-CSF receptor c-Fms [51]. On the 
other hand, Notch also indirectly blunts osteoclasto-
genesis by aﬀ  ecting osteoblastic/stromal cells to decrease 
the OPG/RANKL ratio [51] or M-CSF gene expression 
[50]. However, it should be noted that the inhibitory 
eﬀ  ect of Notch on RANKL-induced osteoclastogenesis is 
modest since the mice with Notch 1/2/3-speciﬁ  c 
deﬁ   ciency in the osteoclast lineage do not exhibit 
signiﬁ   cant defects in physiological bone development 
[51]. In addition, Notch signaling plays an important role 
in proliferation, diﬀ  erentiation and expression of RANKL 
and OPG by osteoblast lineage cells [53-55], and thus 
indirectly regulates osteoclastogenesis in vivo. Th   e role of 
the Notch pathway in inﬂ  ammatory bone resorption has 
not been investigated, and future studies in this area may 
reveal new opportunities for therapeutic intervention.
Transcriptional repressors: Ids, Eos, MafB, C/EBPβ, 
IRF-8, BcL6
Balanced osteoclast diﬀ  erentiation is precisely controlled 
and maintained by complex mechanisms at various 
levels. In the past two decades, extensive studies have 
focused on the activation of signaling cascades that lead 
to activation of transcription factors such as NF-κB, AP-1 
and NFATc1 that promote osteoclast diﬀ  erentiation 
(Figure 2, right). More recently, accumulating evidence 
has revealed that transcriptional repressors expressed 
constitutively in osteoclast precursors function to oppose 
the action of RANK and to restrain osteoclastogenesis 
(Figure 2, left). Th  us, in addition to activating positive 
signaling pathways, RANK needs to overcome the 
‘brakes’ imposed on osteoclast diﬀ  erentiation by trans-
criptional repressors that include inhibitors of diﬀ  eren-
tiation/DNA binding (Ids) [56,57], Eos [58], MafB (v-maf 
musculoaponeurotic ﬁ   brosarcoma oncogene family 
protein B) that is in turn induced by C/EBPβ (CCAAT-
enhancer-binding protein β) [59], IRF-8 [38] and B cell 
lymphoma (Bcl)6 [60]. RANK signaling appears to 
overcome transcriptional repression of genes important 
for osteoclast diﬀ  erentiation and functions, at least in 
part, by downregulating expression of these transcrip-
tional repressors. Th   e need for removal of transcriptional 
repressors for osteoclast diﬀ  erentiation to occur high-
lights their critical roles in negative regulation of 
osteoclastogenesis.
Th   e expression levels of the currently identiﬁ  ed nega-
tive transcription factors Id, Eos, MafB, IRF-8 and Bcl6 
are downregulated by RANKL during osteoclastogenesis 
with diﬀ  erent kinetics. Ids, IRF-8 and MafB are decreased 
at the early stage of osteoclasogenesis, within 24 hours 
after RANKL stimulation, whereas Eos and Bcl6 
expression appear to decrease at later time points. Forced 
expression of Id, MafB, IRF-8 or Bcl6 strongly inhibits 
RANKL-induced osteoclastogenesis in vitro. Eos targets 
Microphthalmia-associated transcription factor (MITF)/
PU.1 target genes for repression, whereas inhibition of 
NFATc1 induction by the other repressors represents a 
common mechanism of suppression of osteoclast 
diﬀ  erentiation. Id proteins associate directly with MITF 
to downregulate expression of osteoclast-associated 
recep  tor (OSCAR) as well as NFATc1, without aﬀ  ecting 
the expression of TREM2, DAP12 or Fc receptor γ. MafB 
proteins interfere with the DNA-binding ability of c-Fos, 
MITF, and NFATc1, thereby inhibiting the transactivation 
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suppresses its DNA binding ability and transcriptional 
activity, thereby inhibiting NFATc1 autoampliﬁ  cation and 
expression of NFATc1 target osteoclast marker genes. 
Bcl6 directly binds to the promoters of NFATc1, dendritic 
cell-speciﬁ   c transmembrane protein (DC-STAMP) and 
cathepsin K, which are NFATc1 targets, to suppress 
osteoclastogenesis.
Deﬁ  ciency of IRF-8 [38], Id1 [57] or Bcl6 [60] in mice 
leads to enhanced osteoclast formation and diﬀ  erent 
extents of osteoporosis, indicating IRF-8, Id1 and Bcl6 
play an inhibitory role in in vivo osteoclastogenesis and 
physiological bone metabolism. Th  e role of MafB in 
physiological bone metabolism in vivo has not been 
reported. Expression of MafB, IRF-8 and Bcl6 is relatively 
selective for hematopoietic cells, whereas expression of 
Ids is observed in diverse cell types, including osteoblasts. 
Th   us, the role of Ids seems to be more complex in vivo. 
Hypoxia-induced Id2 expression is found in rheumatoid 
arthritis synovial ﬁ   broblasts, and promotes synovial 
ﬁ   bro  blast-dependent osteoclastogenesis [61]. Another 
study showed that overexpression of Id1 in prostate 
cancer cells has an important role in promoting prostate 
cancer-mediated osteoclast diﬀ  erentiation, probably via 
certain secreted factors [62]. Th  erefore, the role of Id 
proteins during in vivo osteoclastogenesis in physiological 
and pathological conditions might be regulated by diﬀ  er-
ent cells and dependent on a particular environment.
Th   e role of IRF-8 in inﬂ  ammatory bone resorption was 
studied  in vitro and in vivo [38]. Inﬂ  ammatory  bone 
erosion stimulated by RANK signaling is enhanced by 
inﬂ   ammatory cytokines such as TNF-α that activate 
osteoclastogenesis directly or indirectly via activation of 
stromal cells and osteoblasts. IRF-8 deﬁ  ciency dramati-
cally promotes TNF-α-induced osteoclastogenesis in 
vitro, and results in increased NFATc1 expression, 
indicat  ing that IRF-8 has a suppressive role in TNF-α-
induced osteoclastogenesis. IRF-8 deﬁ  ciency signiﬁ  cantly 
attenuates TLR-induced inhibition of osteoclastogenesis, 
suggesting IRF-8 plays an important part in the inhibitory 
mechanisms of TLRs. In a lipopolysaccharide-induced 
inﬂ   ammatory bone resorption model, IRF-8-deﬁ  cient 
mice exhibit enhanced osteoclast formation and more 
dramatic bone destruction than wild-type littermates. 
Th  ese data indicate that this homeostatic role of IRF-8 
may be important to limit bone resorption during acute 
infections and also in chronic inﬂ  ammatory conditions 
such as rheumatoid arthritis. IRF-8 expression is also 
downregulated during RANKL-induced human osteo-
clastogenesis and silencing of IRF8 mRNA in human 
osteoclast precursors with small interfering RNAs leads 
to enhanced osteoclast diﬀ   erentiation, indicating the 
function of IRF-8 in osteoclastogenesis is well conserved 
in humans and mice.
Th  e mechanisms by which the expression of these 
repressors is downregulated are largely unknown. Recently, 
the transcriptional repressor Blimp1 (B lymphocyte-
induced maturation protein-1), which is induced by 
NFATc1 in response to RANKL stimulation, was shown 
to suppress the expression of IRF-8, MafB [63] and Bcl6 
[60] (Figure 2). Blimp1 deﬁ  ciency attenuates downregu-
lation of IRF-8, MafB and Bcl6 expression after RANKL 
stimulation, and thus Blimp1 promotes osteoclast diﬀ  er-
en  tiation by suppressing expression of its repressors. 
Conversely, Bcl6 can regulate Blimp1 expression and 
IRF-8 can regulate Bcl6 expression. Th  ese  ﬁ  ndings suggest 
a complex network of transcriptional repressors that 
control osteoclast diﬀ  erentiation, and it will be important 
to identify RANKL-induced signaling pathways and 
upstream molecules that control this transcriptional 
network. It will be also interesting to clarify whether 
these transcriptional repressors mediate the eﬀ  ects  of 
inhibitory cytokines and inﬂ   ammatory factors on 
osteoclasts. For example, factors that induce or maintain 
IRF-8 expression in the presence of RANKL would act to 
restrain osteoclast diﬀ   erentiation. IRF-8 expression is 
induced by IFN-γ, and augmented IRF-8 expression may 
contribute to the inhibitory eﬀ  ects of IFN-γ on osteo-
clastogenesis, and also to the well documented suppres-
sive eﬀ  ects of TLRs on osteoclast precursor cells. Identi-
ﬁ   cation of signaling pathways, additional factors, and 
mechanisms that regulate IRF-8 expression and function 
represents a promising approach to control inﬂ  ammatory 
bone loss.
Conclusion
Osteoclastogenesis in vivo is mediated by various factors, 
including cytokines, signaling molecules and transcrip-
tion factors that directly aﬀ  ect osteoclast precursors and/
or indirectly mediate osteoclastogenesis by targeting 
other cell populations, such as osteoblastic/stromal cells, 
synovial cells and T cells. In the latter case, the balance of 
RANKL versus OPG is often regulated to modulate 
osteo  clastogenesis. Both direct and indirect eﬀ  ects need 
to be studied to fully understand the regulation of osteo-
clastogenesis. In addition, many inﬂ  ammatory  factors 
also inﬂ   uence osteoblast diﬀ  erentiation/function  and 
osteoblastic bone formation, for example, the induction 
of Wnt pathway inhibitors Dickkopf (DKK) proteins and 
Frizzled-related proteins in inﬂ  ammatory  arthritis 
[64,65]. Regulation of osteoblast diﬀ  erentiation will impact 
on RANKL/OPG expression [66,67] and anabolic 
function and thus play an important part in physiological 
and pathological bone turnover in vivo; discussion of 
osteoblast diﬀ   erentiation is beyond the scope of this 
review.
It is interesting that the eﬀ  ects of most direct inhibitors 
are highly dependent on the timing of exposure and 
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after RANKL administration (Figure 1). Strikingly, expo-
sure of pre-osteoclasts to TLR ligands and GM-CSF 
several days after the RANK-mediated osteoclast diﬀ  er-
en  tiation program has been initiated actually results in 
increased osteoclastogenesis and bone resorption, 
possibly by mechanisms related to increased cell survival. 
Another attractive explanation for this timing pheno  me-
non could be related to the downregulation of trans-
criptional repressors such as IRF-8 at the early stage of 
osteoclastogensis, thereby diminishing the suppressive 
function of inﬂ   ammatory factors that utilize these 
repressors to suppress osteoclastogenesis.
One key principle that we have tried to develop is that 
the extent of inﬂ   ammatory bone resorption is often 
deter  mined by the balance between opposing factors. 
Th  is includes not only the balance between positive 
osteoclastogenic factors and negative regulators, but also 
opposing eﬀ   ects of individual factors on diﬀ  erent  cell 
types. A striking example of opposing eﬀ  ects is oﬀ  ered by 
TLR ligands that promote osteoclastogenesis by activat-
ing RANKL expression on stromal cells, yet at the same 
time restrain the amount of bone resorption by directly 
inhibiting early osteoclast precursors. In acute infection 
or chronic inﬂ   ammatory diseases such as rheumatoid 
arthritis, osteoclastogenic factors, including RANKL, 
TNF-α and IL-1, are often predominant and/or osteoclast 
precursors in the inﬂ   ammatory microenvironment are 
refractory to inhibitors of osteoclastogenesis, such as 
IL-27, leading to excessive and pathologic bone 
resorption. Th  us,  identiﬁ  cation of additional mechanisms 
and factors that increase the potency of repressors or 
restore cellular responses to suppressive factors may 
represent eﬀ  ective therapies for bone loss.
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